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Alzheimer’s disease (AD) is the most prevalent age‐related
neurodegenerative disease which is mainly caused by aggregated
protein plaques in degenerating neurons of the brain. These
aggregated protein plaques are mainly consisting of amyloid β (Aβ)
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open access at journals.sagepub.com/home/BSA

fibrils and neurofibrillary tangles (NFTs) of phosphorylated tau
protein. Even though the transgenic murine models can recapitulate
some of the AD phenotypes, they are not the human cell models of
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AD. Recent breakthrough in somatic cell reprogramming made it
available to use induced pluripotent stem cells (iPSCs) for patient‐
specific disease modeling and autologous transplantation therapy.
Human iPSCs provide alternative ways to obtain specific human
brain cells of AD patients to study the molecular mechanisms and
therapeutic approaches for familial and sporadic forms of AD.
After differentiation into neuronal cells, iPSCs have enabled the
investigation of the complex aetiology and timescale over which

KEYWORDS

AD develops in human brain. Here, we first go over the pathological

Alzheimer’s disease (AD), induced pluripotent
stem cell (iPSC), amyloid‐beta plaque (Aβ plaque),
neural stem cell (NSC), transplantation, mutation

application of iPSC for disease model and cell transplantation. At

process of and transgenic models of AD. Then we discuss the
last the challenges and future applications of iPSCs for AD will be
summarized to propose cell‐based approaches for the treatment of
this devastating disorder.

1

Introduction

Alzheimer’s disease (AD) is clinically characterized

by memory loss and cognitive impairment, and
affects the living quality of patients. AD is increas‐
ing rapidly within our ageing population. Recent
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studies reported that 3%~5% of population over
the age of 65 is possibly suffered from AD with
an estimated 5~7 million new cases of AD each
year. Pathologically AD is characterized by
deposition of extracellular amyloid plaque and
intracellular neurofibrillary tangle (NFT) [1, 2].
Past studies have shown that AD is mainly caused
by degeneration of neurons throughout the brain
and particularly in the areas of basal forebrain,
hippocampus and cortical brain. It is reported
that the majority of AD cases are late onset
and sporadic, caused by multiple factors which
interacting with environmental exposures. Only
less than 5% of AD cases are familial and are
caused by genetic mutations in the disease genes
of APP, PSEN1, PSEN2 and other related genes
[3–5].
Currently there is no effective treatment to
stop the disease progression of AD. However
the cholinesterase inhibitors (tacrine, donepezil,
rivastigmine, or galantamine) and an N‐methyl‐
D‐aspartate (NMDA) receptor antagonist (Meman
tine) are available for the treatment of AD. Some
anti‐Aβ monoclonal antibodies, γ‐ or β‐secretase
inhibitors were also developed on clinical trials to
inhibit the formation and aggregation of amyloid
β (Aβ) plaques. In addition, some small molecules
and growth factors which can decrease Aβ deposit
are also in the ongoing clinical trials [6–9]. There
is an urgent need to develop innovative therapies
for AD.
AD is mainly affecting the central nervous
system (CNS) of the patients. It is impossible
to obtain brain samples from the patients before
their death to deeply study the pathological
process and treatments of AD. Over the last two
decades, the potential use of stem cells to treat the
memory dysfunction and cognitive impairment
has received growing attention. Specifically, neural
stem cell transplantation as a treatment for
AD offers a novel approach with tremendous
therapeutic potential. Recent advance in somatic

reprogramming has generated induced pluripotent
stem cells (iPSCs) by over‐expressing the KLF4,
SOX2, c‐MYC and KLF4 genes in somatic fibroblasts
or blood cells [10, 11]. The iPSCs are pluripotent
and can be differentiated to neural stem cells or
neurons for modeling the pathological mechanisms,
drug screening and transplantation therapy of
the neurodegenerative diseases. In the in vitro
studies we can also use the iPSCs to identify
new molecular targets to recapitulate the genetic
background of the individual from iPSC models.
Here we discuss the recent application studies
of iPSCs in modeling and treatment of AD.

2

Experimental and clinical studies to
uncover the molecular pathological
mechanisms of AD

In the past 30 years of studies to investigate the
pathological mechanisms of AD by advanced
molecular and cellular technology, the major
discovery is that in degenerating neurons the
Aβ plaques and NFTs were identified as the
pathological hallmarks of AD [12]. In the deve‐
lopment of AD, cholinergic neurons and synapses
are first affected and neurons eventually degenerate
to lead to the formation of Aβ deposit and tau
tangles in different brain regions. Other studies
indicated that glial cells are also involved. Familial
AD cases are mainly caused by the mutations
in amyloid precursor protein (APP), presenilin 1
(PSEN1 or PS1) and presenilin 2 (PSEN2 or PS2).
Sporadic AD patients are usually accredited by
multiple factors including environmental, living
conditions and other risk factors.
The APP gene was the first AD related gene
described in 1991. Later, AD was also found to
be associated with mutated genes at early‐onset
(PSEN1/2). The other AD‐associated genes include
late‐onset genes (apolipoprotein E, ApoE), tau
and several potential risk genes [13, 14]. Studies
showed that the Aβ peptide associated with
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phosphorylated tau protein induced impairments
of neural cells and synaptic plasticity, indicating
tau protein is required for the neurotoxic effects
of Aβ deposits. The hyperphosphorylated tau and
Aβ peptide are found to be directly interacted to
induce aggregation and hyperphosphorylation
of tau protein [15–18]. These Aβ plaques and tau
protein‐related neurofibrillary tangles spread in
all areas of brain and induce the cytotoxicity
and cell death of the neurons. The memory and
language dysfunctions of patients are caused by
increased soluble and insoluble Aβ peptides, which
are produced from the sequential proteolytic
processing of APP. The aggregated Aβ plaque
and tau‐related NFTs are formed in the brain to
induce extensive neuronal degeneration and
neuronal cell death. APP is normally cleaved by
β‐ or γ‐secretase in the cell membranes and is
highly expressed in the CNS to regulate synapse
formation, neurogenesis, axonal transport, cell
signaling and plasticity. When APP is sequentially
cleaved first by β‐ and then γ‐secretase, the Aβ
peptide fragments of 40 or 42 amino acid (Aβ40
and Aβ42) are produced. These Aβ peptides
eventually formed Aβ‐oligomers or Aβ‐polymers
to aggregate in the neural cells to form Aβ plagues
[19]. PSEN1 and PSEN2 are transmembrane
protein components of the γ‐secretase enzyme
which cleaves multiple substrates including APP.
In addition to γ‐secretase activity, PSEN1 or
PSEN2 is also involved in the regulation of the
endosome/lysosome pathway and autophagy [2].
The NFTs are mainly composed of tau aggregates.
In the process of NFT formation, tau protein is
first phosphorylated, and the phosphorylated tau
proteins then aggregate to form highly ordered
fibrils and the NFTs [20, 21]. Because of the
deposits of Aβ plagues and NFTs in the brains
of Alzheimer’s patients, the neural cells shrink
and progressively lead to apoptosis. Such pro‐
grammed cell death occurs first in the brain
regions responsible for memory and language,
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and ultimately spreads to the entire brain. In the
apoptotic process of neuronal cells, cholinergic
neurons and neuronal synapses are first affected
and gradually degenerate to induce brain shrink.
The neurons of many brain regions are then affected
and have amyloid plaques and neurofibrillary
tangles [22–24].

3

Current transgenic animal models to
study AD

To understand the molecular pathogenesis and
search for the therapeutic targets of AD, different
animal models have been developed. Most
transgenic animal models for AD are based on
the disease genes identified from familial AD.
The first successful APP transgenic mice were
generated by over‐expressing the APP gene and
demonstrated Aβ deposit at early age similar
to those of human AD. These mice eventually
developed AD‐like Aβ deposits in the cortex and
hippocampus of their brains by 9~12 months after
birth, but failed to develop tau‐related NFTs
like seen in brains of AD patients [25, 26]. The
transgenic mice over‐expressing PSEN1 were
reported to have some related neuronal loss and
increased Aβ42 in the cortex and hippocampus
of the mouse brains, but abnormal pathological
Aβ deposits of AD were not observed [27].
To overcome the shortages of the single gene‐
transgenic mouse model, a double transgenic
mouse model was generated from a cross between
the transgenic APP line (Tg2576) and transgenic
PSEN1 line (with M146L mutation), and was
shown to develop large numbers of fibrillary Aβ
deposits in cerebral cortex and hippocampus much
earlier than the singly transgenic Tg2576 mice.
The neuron loss was seen to be more severe in
these double transgenic mice with both mutations
of APP and PSEN1 (APPS751L/PS1M146L) and
Aβ plaques in cerebral cortex and hippocampus
were able to be seen compared to that in the
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control mice. The double transgenic mice also
showed a selectively increase in Aβ42 in their
brains. Importantly, a lot of synaptophysin‐
immunoreactive presynaptic boutons (SIPBs)
were seen in the dentate gyrus (SM), stratum
lucidum of area CA3 (SL), and stratum radiatum
of area CA1‐2 (SR) in these double transgenic
mice [28]. This study supported the role of PSEN1
mutations to induce neurodegeneration of the
nervous systems. In order to further explore
the molecular pathological process induced by
combined genetic mutations of three genes, sub‐
sequent triple transgenic mouse model harboring
APP (Swe), PSEN1 (M146V), and tau (P301L)
transgenes was created and was found to have
AD‐relevant pathological features in the brain
regions of these triple transgenic mice. These
triple transgenic mice developed extracellular
Aβ deposits and NFTs. Importantly the triple
transgenic mice showed impaired synaptic plas‐
ticity including long‐term potentiation, synaptic
dysfunction and cognitive function before plaque
and tangle pathology. These three‐gene combined
AD mice further supported the relationships
between Aβ, tau tangles, providing a valuable
model for evaluating potential AD therapeutics
[29, 30]. However the progressive neuronal
degeneration of cortex, hippocampus and other
specific neocortical regions in the human AD
brain is not evident in most of the transgenic
mouse models, and this is a major limitation of
these murine models. Currently there is no mouse
model that can fully reproduce the features of
pathological progression of majority of sporadic
or late‐onset AD cases. To investigate effects of
the intracellular Aβ (iAβ) accumulation on the
molecular neuropathology, the rat transgenic AD
models were also generated by expressing APP
and PSEN1, in which the impact of iAβ on brain
sectional areas of the Golgi apparatus, lysosomes
and lipofuscin bodies was analyzed [31, 32]. A
recent study developed a transgenic rat line

(McGill‐R‐Thy1‐APP) to express the mutant human
APP carrying double mutations. These transgenic
rats have an intraneuronal Aβ accumulation at
about 1 week after birth, which is widespread
throughout different cortical areas and the
hippocampus (CA1, CA2, CA3, and dentate gyrus).
Homozygous transgenic animals eventually pro‐
duce extracellular Aβ deposits and by 6 months
of age, the dense Aβ plaques are able to be
detected and associated with glial activation
and surrounding dystrophic neurites. These rats
were found to have impairment of cognition as
early as at 3 months of age and develop extra‐
cellular Aβ deposits by 6 months of age [33].
Nevertheless few rat models have been reported
to develop both intracellular and extracellular
Aβ accumulation in the degenerating neurons
and behavior dysfunction including cognitive
deficits.

4

Patient‐derived iPSCs for AD Modeling

Since transgenic mouse or rat models cannot
fully recapitulate the pathological characteristics
of Aβ plaques and the tau tangles, and also the
phenotypes of memory and cognitive dysfunctions,
recent iPSC technology provided us the great
opportunity to use the human cell models to study
the pathological process of AD and screening
therapeutic agents for treatment of AD. As we
cannot perform the brain analysis of AD patients,
these iPSCs can be used to study pathological
mechanisms of the diseased neural cells [34].
4.1 Using iPSCs with genetic mutations to
model familial AD
Most available iPSCs are from AD patients who
have genetic mutations in the associated genes.
These iPSCs were used to investigate the neural
phenotypes and electrophysiologically activities,
which are from patients diagnosed with either
familial AD mutations in APP or PSEN1, or from
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patients with the genomic duplication of the
APP gene which results in increased Aβ deposit.
Most studies have shown an increased total Aβ
protein or the specific Aβ42, resulting in an increase
of the Aβ42/40 ratio. An increase in the aggregated
Aβ42 or in the Aβ42/40 ratio accelerates the
disease progression through the production of
toxic oligomeric or fibric aggregated Aβ to form
Aβ deposits in the iPSC‐derived neural cells [35].
Koch et al. reported that PS1‐L166P mutant human
pluripotent stem cells were differentiated to
neural stem cells and neurons which express the
neuron‐specific APP (695) splice variant, BACE1,
and all members of the γ‐secretase complex [36].
These iPSC‐derived neurons also exhibit an increase
in Aβ secretion and respond to the therapeutic
effect by anti‐amyloidogenic compounds, such as
γ‐secretase inhibitors, indicating the usefulness
of iPSCs as human cellular models to study the
molecular mechanisms of AD. Another study
reported iPSCs from familial AD patients with
APP‐E693 deletion and the iPSCs were differen‐
tiated into neural cells [37]. In these iPSC‐derived
neurons and astrocytes, Aβ oligomers were
observed to accumulate and lead to toxicity to
cellular endoplasmic reticulum (ER) and lysosomes.
A subsequent study reported that iPSCs from
patients harboring the APP mutation (V717I) were
induced to differentiate to forebrain neurons [38].
The important finding of this iPSC model is that
mutation‐containing iPSCs require longer time
to mature to neuronal fates. The APP expression
and the levels of Aβ were observed to increase
dramatically in the mutation‐containing neurons
compared to that of normal iPSC‐derived neurons.
In addition, this mutation was found to alter the
initial cleavage site of γ‐secretase, leading to an
increase of specific Aβ42, Aβ38 and phosphorylated
tau in iPSC‐derived neurons with the APP‐V717I
mutation. In the pathogenesis of AD, the AD‐
associated PSEN1 mutation (L166P) caused a
partial functional loss of γ‐secretase, resulting in
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the decreased Aβ40 and an increased Aβ42/40
ratio. To examine if the PSEN1 mutations (A246E,
H163R, and M146L) affect the effectiveness of
γ‐secretase inhibitor and γ‐secretase modulator
(GSM), iPSC‐differentiated neurons were com‐
pared between patients carrying 3 different PSEN1
mutations and normal control individuals. As
a result, mutant PSEN1 neurons exhibited a
significant elevated Aβ42/40 ratio as compared
with the control neurons. Importantly, treating
the iPSC‐derived neurons with a potent anti‐
inflammatory drug GSM identified new bio‐
markers that differs from all previous cell types
and animals tested. This new biomarker panel
consisted of a reduction in Aβ42, Aβ40 and Aβ38
and in the Aβ42/40 ratio, with no change in the
total Aβ levels. This study provided a unique
signature that will more accurately reflect drug
response in human AD patients and in cerebro‐
spinal fluid biomarker changes observed during
GSM treatment [39].
To further validate the reliability of iPSC with
genetic mutations to model pathogenesis of AD,
the genetic mutations can be corrected to examine
the phenotypes and function of the iPSC‐derived
neurons. The availability of CRIPSR/Cas9 gene
editing has generated mutation‐corrected iPSCs
for AD modeling. This gene editing has been used
to create different iPSC lines from AD models
with mutations in APP. The gene‐corrected iPSCs
from AD patients carrying mutations were also
generated to understand the phenotype recovery
of these iPSCs. Using episomal plasmids express‐
ing hOCT4, hSOX2, hKLF4, hL‐MYC, hLIN28
and a short hairpin against TP53, Li et al. showed
that induced pluripotent stem cells derived
from a 48‐year‐old woman carry a heterozygous
mutation in exon 4 of the PSEN1 gene, which
causes a change in amino acid A79V (c.236 C
to T) [40]. This iPSC cell line was reported as a
bona fide iPSC line with normal karyotype. Later
on, the gene‐corrected iPSC line was generated
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by the CRISPR/ Cas9 system to replace the point
mutation T with the wild‐type nucleotide C. iPSC‐
derived basal forebrain cholinergic neurons (BFCN)
with the PSEN2 N141I mutation displayed an
increased Aβ42/40 ratio. Neurons derived from
PSEN2 N141I iPSCs were found to have fewer
numbers of spikes in response to a depolarizing
current. The height of the electrophysiological
action potential was also significantly decreased
in BFCNs with PSEN2 N141I mutation. CRISPR/
Cas9 correction of this PSEN2 point mutation
eliminated the electrophysiological deficit of
increased Aβ42/40 ratio, restoring the number
and height of spikes to the levels of iPSCs from
control individuals. The genome editing analysis
confirms the recovery of mutation‐related changes
induced by Aβ42/40 ratio [41].
Most recently a CRISPR/Cas9 edited APP‐C‐
terminus showed that attenuating APP‐β‐cleavage
and Aβ production were decreased while the
neuroprotective APP‐α‐cleavage was up‐regulated
in APP‐corrected iPSC‐derived neurons. The
cellular and secreted APP products were examined
in APP edited human iPSC‐derived neurons.
C‐terminus selective‐APP editing in both WT
and mutant APP lines revealed that increased
sAPPα in both WT and London lines, suggesting
upregulation of the neuroprotective α‐cleavage
pathway. ELISAs and western blot showed
attenuated secretion of Aβ40/42 and sAPPβ con‐
firming inhibition of the amyloidogenic pathway
in these neurons. Genomic deep sequencing
showed efficient editing of human APP by the
sgRNA, with truncation of the last 36 amino acid
in human embryonic stem cells [42].
iPSC models for understanding of the disease
pathology are mostly used on neuronal cells,
however the astrocytes have also been reported
to contribute to AD. One study generated
functional astrocytes from iPSCs of AD patients
with PSEN1 ΔE9 mutation and gene‐corrected
patients. It was found that AD patient‐derived

astrocytes showed characteristical pathology
of AD, such as increased Aβ production, altered
cytokine release, and disturbance of Ca2+
homeostasis. Furthermore, AD astrocytes were
observed to have increased oxidative stress
and reduced lactate secretion, and compromised
function of astrocytes, compared to that in healthy
neurons. This indicated that astrocytes are playing
important role in AD pathology and suggested
the strength of iPSC‐derived astrocyte models
for disease mechanisms of AD [43].
4.2 Using iPSC ‑ Derived Neurons to model
sporadic AD
Sporadic AD (sAD) accounts for the majority of
the AD cases. A variety of studies have generated
iPSCs from patients with sporadic AD. Some
studies compared the neuron phenotypes of iPSCs
from familial AD with genetic mutation, sporadic
AD and control individuals. It was found that
iPSC‐derived neurons from the APP duplication
patients and sporadic patient exhibited signifi‐
cantly higher levels of the pathological markers
Aβ40, phosphorylated tau (Thr 231) and active gly‐
cogen synthase kinase‐3β (aGSK‐3β) althrough all
neuron cells exhibited normal electrophysiological
activity as compared to controls [44]. A recent
study compared the iPSC‐derived neurons from
patients with early‐onset fAD with mutations in
the PSEN1 gene, patients with late‐onset sAD,
and control individuals without dementia. As a
result, neurons derived from patients with fAD
and patients with sAD exhibited higher levels
of extracellularAβ1‐40 and Aβ1‐42. But, the
Aβ1‐42/Aβ1‐40 ratios were only observed to
be significantly increased in patients with fAD.
Additionally, the increased levels of active
glycogen synthase kinase 3β, a physiological
kinase of TAU were found in neurons derived
from iPSCs of AD patients. Moreover, elevated
sensitivity to oxidative stress was detected in
both fAD‐ and sAD‐derived neurons [45].

https://mc03.manuscriptcentral.com/brainsa

| Brain Science Advances

27

Brain Sci. Adv.

Most of the studies indicated that the
pathological phenotypes of iPSC‐derived neurons
are similar in patients with fAD and sAD. However
a study found that neurons derived from the fAD
patient have a higher susceptibility to Aβ1‐42
oligomers compared with neurons coming from
sAD and healthy individuals [46]. Even though
most studies showed that Aβ production was
increased in iPSC‐derived neurons, few studies
have investigated the Aβ clearance for modeling
AD. In neurons Aβ degradation is primarily
processed through proteolytic degradation and
autophagy. In brain neurons of AD patients, the
clearance and degradation of Aβ by autophagy
is affected to produce increased toxicity of intra‐
cellular Aβ. The increased levels of total tau (tTau)
and phosphorylated tau (pTau) are playing key
roles to increase Aβ aggregation in AD. Several
studies indicated that the tau protein‐induced
pathological process is independent from APP
in iPSC models of AD. In addition to tau and
ApoE, SORL1 is another susceptible risk factor
for sporadic AD (sAD). The pathological effect
of these susceptible genes may be difficult to
analyze with standard in vitro or in vivo models
because of other environmental effects. iPSCs
harboring genetic variation in the SORL1 gene
may contribute to sAD‐related phenotypes in
human brains. The neurons from iPSCs carrying
SORL1 variants show a reduced SORL1 expression
and APP processing were observed by treatment
with brain‐derived neurotrophic factor (BDNF).
Further shRNA knockdown of SORL1 indicated
that the BDNF‐induced APP processing is depen‐
dent on SORL1 expression. This study suggested
that the expression variation in SORL1 is
modulated by common genetic variants which
can contribute to an individual’s risk of developing
sAD [47].
In addition to using iPSCs to investigate the
intracellular Aβ and tau protein pathogenesis,
other molecular mechanisms of AD were also
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explored by the AD model of iPSCs. In order to
model the transcriptome pathology of AD and
to analyze the disease phenotype of the ubiquitin‐
proteasome system (UPS), protein expression
of AD, and GSK3B, a physiological kinase of
tau, were examined in neuronal cells derived
from AD‐iPSCs. After treatment of neurons
from AD‐iPSCs with an inhibitor of γ‐secretase,
phosphorylated tau was down‐regulated. Tran‐
scriptome analysis of AD‐iPS derived neurons
revealed significant changes in the expression
of genes associated with AD and an AD‐related
protein interaction network composed of APP,
GSK3B and others could be generated using
AD‐iPSC derived neurons [48].
iPSC derived neuronal models from patients
with sAD have also been used to investigate
other AD‐related phenotypes such as ER stress,
mitochondrial dysfunction and oxidative stress
[37]. A recent study demonstrated aberrant
mitochondrial function in patient‐derived cells.
The cultured neurons from iPSCs of AD patients
produced more reactive oxygen species (ROS),
displayed higher levels of DNA damage and
increased oxidative phosphorylation chain com‐
plexes. However, these pathological phenotypes
neither correlated with Aβ nor phosphorylated
tau levels. This study therefore highlights the
possibility of additional mechanisms of disease
pathogenesis in the development of sporadic
AD prior to the appearance of amyloid and tau
pathology, suggesting novel therapeutic approaches
need to be used for treatment of sAD [49]. Some
iPSC lines have been generated to model the AD
are summarized in Table 1.

5

iPSCs‐based therapy of AD

Stem cells have been widely investigated as a cell
replacement treatment for AD. The therapeutic
rational is to take advantage of the transplanted
stem cells to replace the degenerated or injured

journals.sagepub.com/home/BSA

28

Brain Sci. Adv.

Table 1 Summary of induced pluripotent stem cell models of Alzheimer’s disease.
AD type

Study
group

Genetic
mutation

Genome
editing

Neuronal
differentiation

Pathological findings

Drug effects

Yagi, et al.,
2011

PS1 A246E /
PS2 N141I

No

Cortical
neurons

↑Aβ42 and Aβ42/40

γ‐secretase inhibitor,
Aβ42 inhibitor reduce
Aβ42

[89]

fAD

fAD

PS1 L166P /
PS1 D385N

No

Cortical
neurons

↑Aβ42/40 (by decreased
Aβ40), partial loss of
γ‐secretase function

γ‐secretase inhibitor,
non‐steroidal
anti‐inflammatory
drugs reduce Aβ

[36]

Koch, et
al., 2012

fAD

Woodruff,
et al.,2013

PS1 ΔE9
(isogenic,
n = 2~3)

TALEN

Cortical
neurons

↑Aβ42/40, impairment
of γ‐secretase activity

γ‐secretase inhibitor
increases Aβ42/40

fAD

Muratore,
et al., 2014

APP V717I

No

Cortical
neurons

↑Aβ42, Aβ38,↑tTau,
pTau co‐localization of
APP and endosome,
↑β‐secretase activity

γ‐secretase inhibitors
decrease Aβ, Aβ
specific antibody
reduces elevated tTau

fAD

Mahairaki,
et al., 2014

PS1 A246E

No

↑Aβ42/40, ↑sAPPβ

—

fAD

Sproul, et
al., 2014

↑Aβ42/40, altered gene
pathways including
NLRP2, ASB9 and NDP

—

fAD

Moore, et
al., 2015

APP V717I
APP dup
PS1ΔI4
PS1 Y115C

fAD

Liu, et al.,
2014

PS1 A246E
PS1 H163R
PS1 M146L

fAD

Choi, et al.,
2014

APP
K670N/M671L
APP V717I
PS1ΔE9

fAD

Oksanen,
et al., 2017

PS1 ΔE9
Non‐isogenic
(N = 3, n = 2)/
isogenic
(N = 2, n = 1)

CRISPR/
Cas9

fAD

Woodruff,
et al., 2016

PS1 ΔE9 (n = 2)
APP V717F
(n = 1) APP
Swedish (n = 2)

TALEN

fAD

Raja, et al.,
2016

APP dup
PS1 M136I
PS1 A264E

fAD

Paquet, et
al., 2016

APP Swedish
PS1 M146V
(N = 1, n = 3)

fAD/ sAD

Jones, et
al., 2017

PS1 A246E
PS1 M146L

PS1 M146L
ApoE 44 (n = 1)

Neural
progenitor
cells (NPCs)

No

Cortical
neurons

No

Neural stem
cells, neurons

mutant PS1 neurons
exhibited an elevated
Aβ42/40 at the basal
state

—

No

Neural
precursor cells,
neurons

↑Aβ40 and Aβ42,
↑Aβ42/40 in PS1ΔE9

β‐ or γ‐secretase
inhibitor decreases Aβ
levels with no
appreciable toxicity

No

γ‐secretase inhibitor
↑Aβ42/40 APP (but not
increases intracellular
PS1) leads to ↑tTau and
tau, while β‐secretase
pTau
inhibitor reduces it

[38]

[72]

[92]

[39]

↑Aβ42/40 (↑Aβ42 but
unchanged Aβ40)/↓ Aβ42
Astrocytes, 3D
uptake/ Disrupted Ca
co‐culture of
signaling and cytokine
astrocyte‐
secretion/ Increased ROS
neurons
and reduced lactate
production

γ‐secretase inhibitor
blocks Aβ42
production

Cortical
neurons

Impaired endocytosis
and transcytosis of APP
and lipoproteins

Phenotypes rescued
by β‐secretase
inhibitors

Organoid

Aβ aggregation, ↑pTau

γ‐secretase and
β‐secretase inhibitors
reduces Aβ and pTau

↑Aβ42/40 in
dose‐dependent manner
of the mutation

—

Astrocytes

[90]

[91]

No

CRISPR / NPCs, Cortical
Cas9
neurons

Refer‐
ences

[93]

[94]

No GFAP changes but
↓S100B, EAAT1 and GS,
morphology changes
and cytosolic
distribution of S100B in
fAD/sAD
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[95]

[96]

[97]

[98]
—
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(Continued)
AD type

Study
group

Genetic
mutation

fAD/sAD

Israel, et
al., 2012

APP dup
sAD (n = 2)

fAD/sAD

Kondo, et
al., 2013

APP E693Δ/
APP V717L
sAD (n = 2) in
Isogenic Human
Stem Cells

fAD/sAD

Duan, et
al., 2014

PS1 A246E
fAD ApoE 34
(n = 3)

Wang, et
al., 2018

Non‐isogenic
(n = 3 per
genotype)/
isogenic ApoE
(n = 1 per
genotype)

sAD‐
ApoE

sAD‐
ApoE

Lin, et al.,
2018

Isogenic ApoE
(N = 1, n = 2 per
genotype)

Genome
editing

Neuronal
differentiation

Pathological findings

Drug effects

No

Cortical
neurons

↑Aβ40, pTau, activated
GSK3β, large endosome
accumulation, sAD
variability

β‐secretase inhibitors
reduce pTau and
GSK‐3β levels

No

Cortical
neurons,
astrocytes

↑Aβ42,↓ Aβ40, Aβ
oligomer accumulation
in APP E693Δ and one
of the two sAD but not
APP V717L

DHA reduces Aβ

No

Cortical
neurons

↑Aβ42/40 of some fAD
and ApoE 34 ApoE 34
are sensitive to
neurotoxic stimuli and
increased Ca2+ level

γ‐secretase inhibitors
decrease Aβ40 in fAD
but increase Aβ40 in
ApoE 34

Cortical
neurons

↑Aβ,↑pTau in ApoE
44, GABAergic neuron
degeneration, ApoE KO
neurons behave similar
to ApoE 33.

Small‐molecule
structure corrector
ameliorates the
detrimental effects in
ApoE 44 neurons

Induced
neurons, glia
organoid

Defects in early neuronal
differentiation in E44
neuron, in clearance of
extracellular Aβ in E4
glia, ↑Aβ aggregates
↑pTau in E4 organoid

—

CRISPR/
Cas9

CRISPR/
Cas9

Refer‐
ences
[44]

[37]

[99]

[100]

[101]

sAD

Young, et
al., 2015

SORL1 risk vs
protective SNPs
(n = 4 P/P, 6 P/
R, 3 R/R)

No

Cortical
neurons

—

Risk variant has no
SORL1 expression or
Aβ changes while
protective variant
increases SORL1 and
decrease Aβ after
BDNF treatment

sAD

Hossini,
et al., 2015

sAD
(N = 1, n = 2)

No

Cortical
neurons

↑pTau,↑GSK3β
activity, ubiquitin
proteasome system

γ‐secretase inhibitor
downregulates pTau

[47]

[48]

N, number of individual; n, number of clones (cell lines); Dup, duplication; P, protective; R, risk

neural cells and release cytokines to activate
the endogenous neurogenesis [50, 51]. Currently
there are several stem cell sources which have
been studied for transplantation therapy of AD.
They include embryonic stem cells (ESCs); fetal
neural stem cells (NSC); adult stem cells (ASCs)
which include hematopoietic stem cells (HSC),
mesenchymal stem cells (MSCs) and olfactory
ensheathing cells (OECs); somatic reprogrammed
cells which include iPSCs and the directly induced
neurons (iN) from somatic cell reprogramming
[52, 53]. Here we focus on the three kinds of cells
as following.
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5.1 Fetal neural stem cell therapy
Human fetal neural stem cells (fNSCs) are isolated
from the fetal brain of the aborted embryos
at 3~4 months of implantation. fNSCs can be
cultured in vitro and have self‐renewal and
neural differentiation potentials. They are able
to differentiate to neurons and glial cells in vitro
and in vivo [54]. Mouse NSCs (mNSCs) from
postnatal day 14 mice were transplanted to
hippocampus of the mouse AD model and were
shown to improve memory deficits of AD mice.
The transplanted NSCs in the hippocampi of the
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mouse brain were found to survive for at least
5 months and differentiate into neurons and
astrocytes [55, 56]. It was also found that tran‐
splanted NSC significantly improve synaptic
connections and increased neuronal number of
host mouse brain, supporting NSCs have some
therapeutic roles for AD.
The therapeutic effect of fNSC transplantation
on cognitive function was investigated in the
APP/PS1 transgenic mouse with age‐dependent
cognitive deficits. It was shown that the bilaterally
transplanted fNSCs into hippocampal regions
were able to improve spatial learning and memory
function in these mice. However, the pathological
Aβ deposits could not be decreased. Transplanted
NSCs were able to proliferate, migrate, and
differentiate into neurons and glial cells. Impor‐
tantly the improved cognitive function was related
to enhanced long‐term potentiation (LTP) and
an increase in the expression of neural proteins
was observed. These proteins are related to
cognitive function and including synaptophysin,
protein kinase C ζ subtypes (PKCζ), tyrosine
receptor kinase B (TrkB), and BDNF. This study
strongly suggested that grafted fNSCs were able
to improve cognitive deficits in APP/PS1 transgenic
mice [57].
A recent study reported that transplanted
fNSCs into bilateral hippocampus of an APP/PS1
double transgenic mouse model of AD improved
the recognition and memory deficits of AD mice.
The transplanted fNSCs migrated dispersedly in
broad brain regions and differentiated into the
neurons and astrocytes. The synaptic and nerve
fibers of the frontal cortex and hippocampus
were found to be significantly increased in the
fNSC‐treated AD mice, indicating the neuronal
connectivity between transplanted human neural
stem cell (hNSC) and AD brains. In addition, the
Aβ plaques were seen to be reduced in frontal
cortex and hippocampus of the mouse brains

with transplanted fNSC compared to that in
wild‐type and PBS‐transplanted APP/PS1 mice
[40]. To overcome the immune‐rejection of human
cells transplanted to mouse AD models, one study
used murine neural stem cells for transplantation
in AD mouse model and found that mNSCs can
increase cognition and improve synaptogenesis
in 3xTg‐AD mice with neuronal loss. They also
reported the evidence that transplantation of
research grade human central nerve system derived
stem cells (HuCNS‐SCs) can improve cognition
in the mouse models of neurodegeneration.
HuCNS‐SC cells were found to migrate and
differentiate into immature neurons and glia,
and significantly increase synaptic and growth‐
associated markers in both 3xTg‐AD and CaM/
Tet‐DTA mice. However, the pathological Aβ or
tau deposits were not reduced by grafted cells in
aged 3xTg‐AD mice [58].
To increase the survival and neural differentia‐
tion of transplanted cells in vivo, some genetic
approaches was ever used to modify fNSCs to
express cellular growth factors nerve growth
factor (NGF) and BDNF to make the fNSC cells
expressing NGF or BDNF. Transplantation of
fNSCs expressing BDNF and NGF was shown
to increase learning and memory function in AD
animals [59]. The transplanted fNSC‐NGF cells
were found to express NGF and improve the
learning and memory function in chemically
induced AD rats [60]. Since the dysfunction of
the cholinergic neurons and decreased activity
of choline acetyltransferase (ChAT) are the main
cause of cognitive deficits in AD, fNSCs were
engineered to express ChAT gene to increase
release of ChAT for restoration of cognitive func‐
tion. Transplantation of fNSC expressing ChAT
to the rats with learning deficit, the learning and
memory function of the rats were improved
with the elevation of ACh levels in cerebrospinal
fluid of the rats, suggesting the engineered fNSCs
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function in vivo [61, 62].
Another type of fNSCs is human olfactory
bulb neural stem cell, or OEC, isolated from the
olfactory bulb tissue of adult or fetus. These cells
are capable of promoting the functions of neurons
and glial cells. OECs were able to secrete neuro‐
trophic factor to increase endogenous neurogenesis
and the survival of the transplanted cells. Some
studies indicated that OECs have been co‐
transplanted with NSCs or other cells to repair
the brain and spinal cord injuries [63–65]. The
expression of choline acetyltransferase was
significantly increased in co‐transplanted animals
than that in transplanted either OECs or NPCs
alone to improve cognitive dysfunction in rat
model [66]. It was also shown that transplantation
of NPCs with OECs to hippocampal regions
promoted better recovery of learning and memory
of animals lesioned with kainic acids [66]. Most
recent genetically modified human olfactory bulb
neural stem cells (OBNSCs) have been shown to
restore cognitive deficit in rat AD model. These
cells were engineered to express human NGF by
lentivirus‐mediated infection and were transplanted
into the hippocampus of AD rats induced with
ibotenic acid. The OBNSCs‐hNGF cells were
found to be differentiated to mature neurons,
oligodendrocytes and astrocytes, and alleviate
the memory and learning functions of the AD
rats [67].
5.2 Embryonic stem cell therapy
Because of limited neural differentiation of the
fetal brain derived‐fNSCs, the pluripotent ESCs
were also studied for transplantation therapy of
AD models. One study compared the effects of
ESC‐derived neuronal precursor cells (ESC‐NPCs)
and the primed ESC‐NPCs (ESC‐PNPCs) for
treatment of rat AD model [68]. The primed‐
NPCs were induced from ESCs by addition of
Shh to the neural induction medium and were
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found to have more cholinergic neurons. After
transplantation, both ESC‐NPCs and ESC‐PNPCs
improved memory deficits of AD rats. This
suggested that the transplantation of mouse
ESC‐NPCs and/or ESC‐PNPCs (commitment to
cholinergic cells in vitro) can promote behavioral
recovery in a rodent model of AD. To track the
migration and in vivo differentiation of ESC‐NPCs,
mouse ESCs labeled with EGFP were induced
into Nestin‐positive NSCs in vitro and were then
transplanted into the Aβ peptide induced rats.
The transplantation of these NPCs into Aβ‐injured
hippocampus significantly improved the memory
function of the Abeta‐injured rats 16 weeks after
transplantation [69]. Human ESCs were also
differentiated into mature BFCNs for the treatment
of AD. After transplantation into the basal
forebrain of AD model mice, both mouse and
human ESC‐derived BFCN progenitors differentiate
into mature cholinergic neurons in vivo and
improved the learning and memory functions of
AD model mice [70].
5.3 Induced pluripotent stem cells therapy
Recent advance in somatic cell reprogramming
has provided therapeutic potential for neurode‐
generative diseases. iPSCs were generated by
over‐expressing four transcription genes of OCT4,
SOX2, c‐MYC and KLF4 in skin fibroblast cells,
blood cells and urine cells. iPSCs can be derived
from patients themselves and can be differentiated
into any type of cells including neurons and glial
cells. Thus, iPSCs overcome the immune rejections
and ethical issues of heterogeneous stem cell
transplantation and will have better efficacy for
treatment of neurodegenerative diseases including
AD. Earlier iPSCs were generated by retroviral or
lentiviral vectors to express OCT4, SOX2, c‐MYC
and KLF4, these exogenous genes and the retroviral
or lentiviral vectors may integrate to genome of
the iPSCs to cause mutations in iPSCs. Thus, the
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retroviral or lentiviral‐induced iPSCs may not be
suitable for cell‐based therapy. The transgene‐free
iPSCs can be derived by episomal plasmids
or synthetic mRNA technology [71]. Recently
the transgene‐free iPSCs were derived from AD
patients with PS1 mutation (A246E) using non‐
integrating episomal vectors. These iPSCs
harboring PS1 gene mutation could be used as
human models to study pathogenesis and screen
therapeutic drugs for AD. Neurons from the
mutant iPSC lines were found to express PS1‐
A246E mutations and have Aβ deposits as shown
in brain of AD patients [72]. The protein‐based
reprogramming can generate iPSCs more suitable
for transplantation therapy because these iPSCs
are non‐tumorigenic.
The iPSCs were also reported derived from
mouse skin fibroblasts by protein extracts of
embryonic stem cells. The protein‐based mouse
iPSCs were able to be differentiated into glial
cells and reduced the level of Aβ40, Aβ42, and
Aβ deposit in the brains of 5XFAD transgenic
mouse model compared with saline‐injected
control 5XFAD mice after transplantation. The
transplanted protein‐iPSCs were found to decrease
the cognitive dysfunction observed in these
mice [73].
However, the iPSC‐derived neurons still carry
mutations of the APP, PS1 and PS2 genes, these
mutated neurons cannot be directly transplanted
to AD patients for therapy. To resolve this problem,
several approaches have been developed to
correct the mutations in the mutant iPSCs by
homologous recombination in other studies
and then the mutation‐corrected neurons can be
transplanted to patients for the treatment of AD
[42, 74, 75].
In addition to the differentiated neurons of
iPSCs, the therapeutic potential of human iPSC‐
derived macrophage‐like cells for AD was also
explored. Human iPSCs‐derived macrophages

were engineered to express neprilysin‐2, the
Aβ‐degrading protease to therapeutically reduce
Aβ levels after transplanted to a transgenic mouse
AD model. The iPSC‐derived macrophage‐like
myeloid lineage (iPS‐ML) cells was made to
express the Fc‐receptor‐fused form of a single
chain antibody specific to Aβ and Neprilysin‐2
(NEP2) which is a protease with Aβ‐degrading
activity. In vitro expression of NEP2 enhanced the
effect to reduce the level of soluble Aβ oligomer
in the culture medium and to alleviate the
neurotoxicity of Aβ. To analyze the therapeutic
effect of iPS‐ML expressing NEP2 (iPS‐ML/NEP2)
in vivo, the iPS‐ML/NEP2 was transplanted to
5XAD mice. A significant reduction in the level
of Aβ in the brain interstitial fluid of 5XAD mice
was observed. This study suggested that iPS‐ML/
NEP2 may be a potential therapeutic cell for the
treatment of AD [76].
5.4 The molecular mechanisms of stem cell
transplantation
The molecular mechanisms stem cell transplan‐
tation played to improve the memory and
cognition in animal models of AD is not clear,
but several aspects of mechanisms have been
investigated and the possible mechanisms include
cell replacement, release of neurotrophic and
neuroprotective factors, endogenous activation
of neurogenesis, anti‐inflammatory activities, stem
cells as carriers to deliver therapeutic proteins to
the degenerated regions of brain to decrease Aβ
deposits. Neural stem cells can express many
neurotrophins including BDNF and NGF [77].
BDNF, glia‐derived neurotrophic factor (GDNF)
and NGF are the major factors playing regulatory
functions in synaptic plasticity. Rats with traumatic
brain injury (TBI) were intravenously treated with
hMSCs. The extracts from the entire traumatized
cerebral hemispheres with grafts 24 h after TBI
showed significantly increased expression of NGF,
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BDNF, and neurotrophin‐3 (NT‐3) [78]. Stem cells
can secrete anti‐inflammatory factors such as
interleukin‐10, an anti‐inflammatory cytokine and
prostaglandin E2 to inhibit the inflammatory
process of AD. Transplantation of NSCs can also
influence endogenous neurogenesis of the hosts.
The transplantated NSCs derived from human
embryonic stem cells reduced infarct volume
and improved behavioral outcome after distal
middle cerebral artery occlusion (MCAO) in rats.
Jin et al. reported that, transplantation was able
to increase neurogenesis expressing doublecortin
(Dcx) in subventricular zone (SVZ), but not in
contralateral SVZ or dentate gyrus zone (SGZ) of
the rat brains 60 days post‐transplantation [79].
To determine if MSC stimulates endogenous
neurogenesis, MSC was transplanted to the
normally restrictive SVZ of mice and was found to
increase proliferation and neuronal differentiation
of neural progenitors within the SVZ. The pro‐
portion of the newborn neurons was increased
out of the total proliferating cells [80]. A recent
study showed that adipose‐derived MSC
transplanted into the hippocampi of APP/PS1
transgenic AD mice significantly increased
number of BrdU/DCX‐stained cells in the in the
subventricular zone of the dentate gyrus in the
hippocampus, suggesting that MSC transplantation
improve the memory and cognitive functions
by enhancing the neurogenesis of the APP/PS1
transgenic AD mice [81]. BM‐MSCs were shown
to increase leukocyte activation and promote
leukocyte‐endothelial interactions. BM‐MSCs were
found to significantly inhibit transcriptional
activation of NF‐kappa B and inhibit DNA
binding of NF‐kappa B subunits p50 and p65 to
putative NF‐kappa B DNA binding sites by the
direct effects of MSCs on IL‐10 and NF‐kB [82].
In a study that focused on alleviating amyloid
pathology through transplanted NSCs from
postnatal mice, the NSCs was modified to express
metalloproteinase 9 (MMP9), a protease to degrade
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aggregated Aβ peptides. Even though some
endogenous MMP9 was detected around amyloid
plaques in the mouse models, no stem cell‐
delivered MMP9 was found to have impact on
the Aβ plaques. This study suggested that the
delivering approach may be required to enhance
therapeutic efficacy of the transplanted cells [83].
To know how transplanted cells to improved
spatial memory, hNSCs were injected into the
cerebral lateral ventricles of APPsw‐expressing
(APPsw) transgenic mice at 13 months of age,
it was found that Aβ production was reduced
through an Akt/GSK3β‐signaling‐mediated decrease
in BACE1, and the expression of inflammatory
mediators was decreased through deactivation
of microglia [84].
To increase the production efficiency of iPSC‐
derived neuronal cells, the automated repro‐
gramming and the pooled selection of polyclonal
pluripotent cells have generated high‐quality and
stable iPSC lines. These lines display less line‐to‐
line variation than either manually produced lines
or lines produced through automation followed
by single‐colony subcloning. This platform will
enable the application of iPSCs to population‐scale
biomedical problems including the study of
complex genetic diseases and the development of
personalized iPSC‐based transplantation therapy
[85].

6

Clinical studies of stem cell
transplantation

The experimental evidence for the safety and
efficacy of stem cell‐based therapies for AD
through animal models strongly supported the
approval of several clinical trials. Most of the
clinical studies used MSCs from human umbilical
cords and bone marrows. In a phase I study
conducted in South Korea, human umbilical cord
blood mesenchymal stem cells (hUCB‐MSCs)
were injected to AD patients with mini‐mental
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state examination (MMSE) scores between 10 and
24 to exclude severe AD subjects. The included
subjects were divided into 3 groups: a stem cell
high‐dose group (6.0 × 106 cells), a low‐dose group
(3.0 × 106 cells) and a treated control group.
hUCB‐MSCs were injected into the bilateral
hippocampus and precuneus directly. Subjects
were evaluated after 12 weeks and continue for
24 months by brain computerized tomography
(CT), magnetic resonance imaging (MRI),
fludeoxyglucose positron emission tomography
(FDG‐PET), blood samples and clinical evaluation.
It was reported that no severe acute or long‐term
side effects or significant clinical efficacy were
found [86, 87]. A multicenter, randomized, placebo‐
controlled and double‐blinded phase I/II study
started in 2016, in which forty subjects with
probable AD and mixed dementia according
to the criteria of the NINCDS‐ADRDA were
intravenously infused with hUCB‐MSCs 8 times
at 2‐week intervals. This study will compare
blood, cerebrospinal fluid (CSF), and neuro‐
psychological assessments among different groups
(Clinicaltrials.gov, NTC02672306). Other clinical
studies using different injection routes, well‐
established scales, and biomarkers such as amyloid
positron emission tomography, are planned for
stem cell transplantation to moderate AD patients
are ongoing. Recently the clinical cell therapy
guidelines for cell‐based therapy of neurological
diseases were formed to improve the therapeutic
effects and standardization of the cell transplan‐
tation to the patients [88]. It is believed that
advances in iPSCs technology will enable deve‐
lopment of stem cell‐based therapeutic approaches
to increase the clinical use of the stem cell
products in AD.

damaged cells for the treatment of AD. Although
preclinical studies showed substantial efficacy of
stem cell transplantation in AD, few trials showed
positive results. Thus, not only do we need to
further understand the mechanisms underlining
the pathological process of AD and regulating
the proliferation, migration, differentiation,
survival, and function of iPSCs, but also employ
translational models to bridge this gap between
the animal studies and clinical trials. Some stem
cell sources such as BM‐MSC, UC‐MSC, and
UCB‐MSC are easily accessible; however these
cells have limited neural differentiation and may
induce immune rejections as they are allogenic.
Human ESCs and NSCs have ethical and
immune rejection issues which hindered their
clinical application in AD therapy. The iPSCs are
derived from reprogrammed somatic cells such
as fibroblasts, blood or urine cells of patients
themselves and overcome the immune rejection
and ethical issues on stem cells. Thus patient‐
specific iPSCs will have invaluable potential for
treatment of AD. As the mechanisms of AD are
eventually elucidated by animal and human iPSC
models, the iPSC‐based therapy will become more
and more important. The differentiated cell types
are major concerns. Some factors such as cell
proliferation, differentiation, migration, unity with
neural stem cells are also crucial to the actual
use of iPSCs. Before the iPSCs are moving to AD
patients, several aspects on mutation correction,
neural differentiation, purification and long‐term
survival of iPSCs following transplantation need
to be resolved and standardized to make clinical‐
grade iPSCs suitable for the AD patients.

7

Dong Han is working as a research assistant
for animal studies in the Shandong Molecular
Diagnosis & Cell Therapy Biotechnology
Corporation.

Conclusions

iPSCs are pluripotent cells and are able to
differentiate to neural lineages to replace the
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